Patent intelligence · US
US 12139711
Antisense oligonucleotides for the treatment of Leber congenital amaurosis
Antisense oligonucleotides for the treatment of Leber congenital amaurosis
Patent details — US 12139711
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 12, 2024
- Expiration
- Nov 7, 2044
- Claims
- 23
- CPC classes
- A61P, A61P27/02
Quick answer
US 12139711 (Antisense oligonucleotides for the treatment of Leber congenital amaurosis) is held by Stichting Radboud universitair medisch centrum. Status: granted. Granted Nov 12, 2024. Expires Nov 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61P, A61P27/02
More from Stichting Radboud universitair medisch centrum
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 12139711?
US 12139711 (Antisense oligonucleotides for the treatment of Leber congenital amaurosis) is held by Stichting Radboud universitair medisch centrum. Status: granted. Granted Nov 12, 2024. Expires Nov 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12139711?
Stichting Radboud universitair medisch centrum is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 12139711 expire?
Our index shows an expiration date of Nov 7, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.